Considering the Experimental Use of Temozolomide in Glioblastoma Research

Temozolomide (TMZ) currently remains the only chemotherapeutic component in the approved treatment scheme for Glioblastoma (GB), the most common primary brain tumour with a dismal patient’s survival prognosis of only ~15 months. While frequently described as an alkylating agent that causes DNA damag...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biomedicines
Main Authors: Herbener, Verena J., Burster, Timo, Goreth, Alicia, Pruss, Maximilian, von Bandemer, Hélène, Baisch, Tim, Fitzel, Rahel, Siegelin, Markus D., Karpel-Massler, Georg, Debatin, Klaus-Michael, Westhoff, Mike-Andrew, Strobel, Hannah
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7344626/
https://ncbi.nlm.nih.gov/pubmed/32512726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines8060151
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados